These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 38545699)
1. Efficacy of 300 IR house dust mite immunotherapy as a function of disease activity: Tertile analysis in clinical trials. Devillier P; Demoly P; Gentil C; Bergmann KC; Casale TB; Okamoto Y; Pfaar O Clin Exp Allergy; 2024 May; 54(5):329-338. PubMed ID: 38545699 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis. Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024 [TBL] [Abstract][Full Text] [Related]
4. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial. Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778 [TBL] [Abstract][Full Text] [Related]
5. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. Calderon MA; Casale TB; Nelson HS; Demoly P J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829 [TBL] [Abstract][Full Text] [Related]
6. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial. Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432 [TBL] [Abstract][Full Text] [Related]
7. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial. Demoly P; Corren J; Creticos P; De Blay F; Gevaert P; Hellings P; Kowal K; Le Gall M; Nenasheva N; Passalacqua G; Pfaar O; Tortajada-Girbés M; Vidal C; Worm M; Casale TB J Allergy Clin Immunol; 2021 Mar; 147(3):1020-1030.e10. PubMed ID: 32890575 [TBL] [Abstract][Full Text] [Related]
8. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration. Bernstein DI; Kleine-Tebbe J; Nelson HS; Bardelas JA; Sussman GL; Lu S; Rehm D; Svanholm Fogh B; Nolte H Ann Allergy Asthma Immunol; 2018 Jul; 121(1):105-110. PubMed ID: 29656145 [TBL] [Abstract][Full Text] [Related]
9. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases. Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977 [TBL] [Abstract][Full Text] [Related]
10. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis. Demoly P; Kleine-Tebbe J; Rehm D Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339 [TBL] [Abstract][Full Text] [Related]
11. 300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis. Demoly P; Okamoto Y; Yang WH; Devillier P; Bergmann KC Expert Rev Clin Immunol; 2016 Nov; 12(11):1141-1151. PubMed ID: 27632814 [TBL] [Abstract][Full Text] [Related]
12. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population. Okamoto Y; Fujieda S; Okano M; Hida H; Kakudo S; Masuyama K Pediatr Allergy Immunol; 2019 Feb; 30(1):66-73. PubMed ID: 30281866 [TBL] [Abstract][Full Text] [Related]
14. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease. Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268 [TBL] [Abstract][Full Text] [Related]
15. House dust mite sublingual immunotherapy in allergic rhinitis. Cho SW; Han DH; Kim JW; Kim DY; Rhee CS Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802 [TBL] [Abstract][Full Text] [Related]
16. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial. Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sublingual tablets of house dust mite allergen extracts: Results of a dose-ranging study in an environmental exposure chamber. Roux M; Devillier P; Yang WH; Montagut A; Abiteboul K; Viatte A; Zeldin RK J Allergy Clin Immunol; 2016 Aug; 138(2):451-458.e5. PubMed ID: 27289490 [TBL] [Abstract][Full Text] [Related]
19. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Okamoto Y; Fujieda S; Okano M; Yoshida Y; Kakudo S; Masuyama K Allergy; 2017 Mar; 72(3):435-443. PubMed ID: 27471838 [TBL] [Abstract][Full Text] [Related]
20. House Dust Mite Sublingual Immunotherapy for Pediatric Patients With Allergic Asthma. Richards JR; Stumpf JL Ann Pharmacother; 2018 Oct; 52(10):1019-1030. PubMed ID: 29642713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]